I’m a forensic linguist (independent and recently long on CYDY) and reviewed Dr. Nader Pourhassan’s interview on YouTube (https://www.youtube.com/watch?v=WiyjIIpkIJw&feature=youtu.be). Here are my impressions:
- [ ] Caveats: Dr. Pourhassan is a non-medical mind, a businessman, a highly educated engineer, not a medical mind. Therefore, if he believes what he says it is because he believes the medical minds telling him. That is good for us in one way because it helps us know what his scientists are telling him. On the other hand, his responses show he believes as a relative layperson but one with important personal and inside information. I haven’t analyzed interviews of his scientists. Further, this is the only video I’ve analyzed on Dr. Pourhassan so I have no other samples with which to compare - which puts my conclusions/observations at a lower confidence level.
- [ ] The interviewer, Dr. Been, is pro CYDY - as a researcher/scientist that is good for CYDY stockholders to have a medical mind who likes what he’s seeing. It somewhat detracts from his objectivity. Nevertheless, he asked good questions and allowed Dr. Pourhassan to respond, without interruption. This is an excellent video and interview.
- [ ] Dr. Pourhassan showed signs of truthful and genuine responses:
- [ ] Voice inflection stable and consistent with verbal and bodily responses; other body movements (eyes, eyebrows, lip movements, hand movements, facial ticks, etc) all showed Dr. Pourhassan believes in what he is telling us.
- [ ] I really like his easy and fluent use of the pronouns, “I, my, and we.” He uses them appropriately, at the right time and in the right context for truthfulness. That shows commitment and belief.
- [ ] The one question wherein Dr. Pourhassan showed uneasiness and waffling was the question about setting the price for Leronlimab. He showed an unusually volatile response - and I’m not sure what that means. It may mean he is very unsure of pricing, reflecting the very complex ingredients leading to a decision.
- [ ] Overall, I’m impressed with Dr. Pourhassan’s performance and response. He energetically believes in Leronlimab and its prospects.
- [ ] Caveats: Dr. Pourhassan is a non-medical mind, a businessman, a highly educated engineer, not a medical mind. Therefore, if he believes what he says it is because he believes the medical minds telling him. That is good for us in one way because it helps us know what his scientists are telling him. On the other hand, his responses show he believes as a relative layperson but one with important personal and inside information. I haven’t analyzed interviews of his scientists. Further, this is the only video I’ve analyzed on Dr. Pourhassan so I have no other samples with which to compare - which puts my conclusions/observations at a lower confidence level.
- [ ] The interviewer, Dr. Been, is pro CYDY - as a researcher/scientist that is good for CYDY stockholders to have a medical mind who likes what he’s seeing. It somewhat detracts from his objectivity. Nevertheless, he asked good questions and allowed Dr. Pourhassan to respond, without interruption. This is an excellent video and interview.
- [ ] Dr. Pourhassan showed signs of truthful and genuine responses:
- [ ] Voice inflection stable and consistent with verbal and bodily responses; other body movements (eyes, eyebrows, lip movements, hand movements, facial ticks, etc) all showed Dr. Pourhassan believes in what he is telling us.
- [ ] I really like his easy and fluent use of the pronouns, “I, my, and we.” He uses them appropriately, at the right time and in the right context for truthfulness. That shows commitment and belief.
- [ ] The one question wherein Dr. Pourhassan showed uneasiness and waffling was the question about setting the price for Leronlimab. He showed an unusually volatile response - and I’m not sure what that means. It may mean he is very unsure of pricing, reflecting the very complex ingredients leading to a decision.
- [ ] Overall, I’m impressed with Dr. Pourhassan’s performance and response. He energetically believes in Leronlimab and its prospects.
24
